Trial · NCT01946295
Famotidine in Schizophrenia
NCT01946295, Phase 2, Phase 3, Unknown, Jesper Ekelund
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Famotidine in Schizophrenia. Trials, record NCT01946295. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01946295
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Famotidine in Schizophrenia
- NCT number
- NCT01946295
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 140 participants, estimated
- Lead sponsor
- Jesper Ekelund
- Conditions
- Schizophrenia
- Interventions
- Famotidine, Placebo
- First posted
- 2013-09-19
- Last updated
- 2015-04-14
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Positive and Negative Syndrome Scale (PANSS) at 8 weeks | Rating at start of treatment (0 weeks) and at end of treatment (8 weeks) | In addition PANSS ratings are done at screening, every two weeks during treatment and two weeks after end of treatment. |
| Secondary | Change from Baseline in Clinical Global Impression (CGI) scale at 8 weeks | Rating at start of treatment (0 weeks) and at end of treatment (8 weeks) | In addition CGI ratings are done at screening, every two weeks during treatment and two weeks after end of treatment. |
| Secondary | Change from Baseline in Calgary Depression Scale (CDS) at 8 weeks | Rating at start of treatment (0 weeks) and at end of treatment (8 weeks) | |
| Secondary | Change from Baseline in The Overall Anxiety Severity and Impairment Scale (OASIS)at 8 weeks | Rating at start of treatment (0 weeks) and at end of treatment (8 weeks) | |
| Secondary | Change from Baseline in CogState scores at 8 weeks | Rating at start of treatment (0 weeks) and at end of treatment (8 weeks) | A standardized, language independent computerized battery of cognitive tests (CogState®). This battery has been validated and shown to be a sensitive indicator of mild impairments in the following cognitive domains: psychomotor speed, attention, working memory and episodic learning and memory. |
| Secondary | Change from baseline in nightly sleep duration measured with actigraphy at 8 weeks | Measurement at start of treatment (0 weeks) and at end of treatment (8 weeks) | Average nightly sleep duration of seven nights before and after intervention measured with an actigraph |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23764683 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01946295
GET https://conductscience.org/api/trials/v1/NCT01946295/registered